Search Orphan Drug Designations and Approvals
-
| Generic Name: | an autologous, epigenetically modified cell therapy product which contains expanded tumor-infiltrating lymphocytes (TIL) |
|---|---|
| Date Designated: | 11/06/2023 |
| Orphan Designation: | Treatment of Stage IIB-IV Melanoma |
| Orphan Designation Status: | Designated/Designation Withdrawn or Revoked |
| FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
| Sponsor: |
Lyell Immunopharma, Inc. 201 Haskins Way South San Francisco, California 94080 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







